Reflecting on PEGS Europe 2023
Drug Discovery World
NOVEMBER 30, 2023
The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. It was presented by Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, and titled: ‘AI-based target and antibody discovery from patient tumour profiles’.
Let's personalize your content